{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:48:26Z","timestamp":1792165706497,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xcrm.2026.103116","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:05:56Z","timestamp":1792163156000},"page":"103116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["NKG2D overexpression potentiates CAR-T cells through costimulation by tumor NKG2D ligands"],"prefix":"10.1016","author":[{"given":"Jiajia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianshu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-3899","authenticated-orcid":false,"given":"Weidong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103116_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103116_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.seminhematol.2023.11.007","article-title":"CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?","volume":"60","author":"Kinoshita","year":"2023","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.xcrm.2026.103116_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/hematology.2023000424","article-title":"Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells","volume":"2023","author":"Talleur","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.xcrm.2026.103116_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.xcrm.2026.103116_bib5","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","article-title":"CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy","volume":"8","author":"Ledergor","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.103116_bib6","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","article-title":"Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology","volume":"9","author":"Watanabe","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.103116_bib7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.103116_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.103116_bib9","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/biom12091303","article-title":"Co-Stimulatory Receptor Signaling in CAR-T Cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.xcrm.2026.103116_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: Functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.xcrm.2026.103116_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm1463","article-title":"Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies","volume":"14","author":"Goodman","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103116_bib12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103116_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2026.103116_bib14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.xcrm.2026.103116_bib15","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00262-020-02838-8","article-title":"CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors","volume":"70","author":"Chen","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.103116_bib16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12967-023-04372-4","article-title":"Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality","volume":"21","author":"Smith","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103116_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.103116_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103116_bib19","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103116_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-023-03586-1","article-title":"Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.103116_bib21","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.stem.2024.06.011","article-title":"Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies","volume":"31","author":"Hammer","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.103116_bib22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fimmu.2012.00408","article-title":"NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses","volume":"3","author":"Zingoni","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.103116_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2006-10-052720","article-title":"Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM\/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis","volume":"110","author":"Cerboni","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.103116_bib24","doi-asserted-by":"crossref","first-page":"17545","DOI":"10.3390\/ijms242417545","article-title":"The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy","volume":"24","author":"Wei","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.103116_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.virol.2013.04.037","article-title":"Viral protein R upregulates expression of ULBP2 on uninfected bystander cells during HIV-1 infection of primary CD4+ T lymphocytes","volume":"443","author":"Richard","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2026.103116_bib26","article-title":"Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells","volume":"5","author":"Obajdin","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.103116_bib27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\u2013CD80 interaction","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103116_bib28","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41590-023-01671-2","article-title":"CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity","volume":"24","author":"Tang","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.103116_bib29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/cmi.2017.161","article-title":"Functions of NKG2D in CD8(+) T cells: an opportunity for immunotherapy","volume":"15","author":"Prajapati","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.xcrm.2026.103116_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ni1043","article-title":"Cis association of Ly49A with MHC class I restricts natural killer cell inhibition","volume":"5","author":"Doucey","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.103116_bib31","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1073\/pnas.0607418104","article-title":"Stable masking by H-2Dd cis ligand limits Ly49A relocalization to the site of NK cell\/target cell contact","volume":"104","author":"Back","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103116_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adj7970","article-title":"The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance","volume":"9","author":"Kilian","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2026.103116_bib33","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","article-title":"A pan-cancer single-cell panorama of human natural killer cells","volume":"186","author":"Tang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103116_bib34","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.trecan.2025.08.014","article-title":"CAR T cell persistence in cancer","volume":"11","author":"Mueller","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2026.103116_bib35","first-page":"213","article-title":"Impact of T cell characteristics on CAR-T cell therapy in haematological malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2026.103116_bib36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.103116_bib37","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.4049\/jimmunol.170.7.3572","article-title":"Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells","volume":"170","author":"Rabinovich","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.103116_bib38","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1189\/jlb.71.5.791","article-title":"Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28","volume":"71","author":"Molinero","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.xcrm.2026.103116_bib39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ni1325","article-title":"NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells","volume":"7","author":"Upshaw","year":"2006","journal-title":"Nat. Immunol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:06:00Z","timestamp":1792163160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126005331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"alternative-id":["S2666379126005331"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103116","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NKG2D overexpression potentiates CAR-T cells through costimulation by tumor NKG2D ligands","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103116"}}